| Host: |
Rabbit |
| Applications: |
WB/ELISA/IHC |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Nucleotide exchange factor SIL1 (169-219 aa) is suitable for use in Western Blot, ELISA and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-2000IHC-P 1:50-300ELISA 2000-20000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
SIL1 |
| Gene ID: |
64374 |
| Uniprot ID: |
SIL1_HUMAN |
| Immunogen Region: |
169-219 aa |
| Specificity: |
This antibody detects endogenous levels of SIL1 at Human/Mouse/Rat |
| Immunogen: |
Synthesized peptide derived from the human SIL1 at the amino acid range 169-219 |
| Post Translational Modifications | N-glycosylated. Ubiquitinated by the CRL2(FEM1A) and CRL2(FEM1C) complexes, which recognize the -Lys-Xaa-Xaa-Arg C-degron at the C-terminus, leading to its degradation. |
| Function | Required for protein translocation and folding in the endoplasmic reticulum (ER). Functions as a nucleotide exchange factor for the ER lumenal chaperone HSPA5. |
| Protein Name | Nucleotide Exchange Factor Sil1Bip-Associated ProteinBap |
| Cellular Localisation | Endoplasmic Reticulum Lumen |
| Alternative Antibody Names | Anti-Nucleotide Exchange Factor Sil1 antibodyAnti-Bip-Associated Protein antibodyAnti-Bap antibodyAnti-SIL1 antibodyAnti-UNQ545 antibodyAnti-PRO836 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
